{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mc Causland FR"],"funding":["NIDDK NIH HHS"],"pagination":["1591-1598"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9253196"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(9)"],"pubmed_abstract":["<h4>Aims</h4>Patients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin-neprilysin inhibition in a pooled analysis of 13 195 patients with heart failure with reduced and preserved EF.<h4>Methods and results</h4>We combined data from PARADIGM-HF (EF ≤40%; n = 8399) and PARAGON-HF (EF ≥45%; n = 4796) in a pre-specified pooled analysis. We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope. We assessed whether baseline renal function or EF modified the effect of therapy on renal outcome"],"journal":["European journal of heart failure"],"pubmed_title":["Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure."],"pmcid":["PMC9253196"],"funding_grant_id":["U01 DK096189","K23 DK102511","R03 DK122240"],"pubmed_authors":["Swedberg K","Pfeffer MA","Senni M","McMurray JJV","Zannad F","Shi V","McGrath MM","Mc Causland FR","Packer M","Jhund PS","Vaduganathan M","Gori M","Solomon SD","Claggett B","Zile M","Lefkowitz MP","Rouleau JL"],"additional_accession":[]},"is_claimable":false,"name":"Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.","description":"<h4>Aims</h4>Patients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin-neprilysin inhibition in a pooled analysis of 13 195 patients with heart failure with reduced and preserved EF.<h4>Methods and results</h4>We combined data from PARADIGM-HF (EF ≤40%; n = 8399) and PARAGON-HF (EF ≥45%; n = 4796) in a pre-specified pooled analysis. We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope. We assessed whether baseline renal function or EF modified the effect of therapy on renal outcome","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T01:27:32.736Z","creation":"2025-04-07T12:14:06.325Z"},"accession":"S-EPMC9253196","cross_references":{"pubmed":["34989105"],"doi":["10.1002/ejhf.2421"]}}